Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "TILT[LastUpdatePostDate]SEARCH[Study]AREA[SponsorSearch]Fujian Cancer Hospital"
Count: 108
Selected: 0
| NCT ID | Title |
|---|
| NCT04421469 | Triprilimab(JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC | ||
| NCT04319471 | Sufficient Chemotherapy Combine With Maintenance Chemotherapy in the Treatment of Oligometastatic Nasopharyngeal Carcinoma | ||
| NCT04220528 | Radical Radiotherapy and Chemotherapy Combined With Maintenance Chemotherapy in the Treatment of Stage N3 NPC | ||
| NCT05335460 | To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer | ||
| NCT05319639 | Phase I Study of the Combination of Irinotecan and POF (POFI) | ||
| NCT05314101 | TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer | ||
| NCT05266820 | Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer | ||
| NCT05223088 | Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer | ||
| NCT05192681 | Tislelizumab as Cross-line Treatment for Advanced NSCLC | ||
| NCT03666221 | Nimotuzumab for Recurrent Nasopharyngeal Carcinoma | ||
| NCT05007145 | PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | ||
| NCT05131243 | the Role of ctDNA in Predicting the Recurrence Risk of Colorectal Cancer | ||
| NCT04764006 | Surufatinib Combined With Sintilimab for Advanced MSS-Type Colorectal Cancer : a Phase II Study | ||
| NCT05001360 | Study of FMT Combined With Nivolumab in Gastric Cancer | ||
| NCT05035446 | Short-term Outcomes of SILS+1 Versus CLS for Distal Gastric Cancer | ||
| NCT05049811 | Effects of Mobile Medicine on Cancer Patients | ||
| NCT05019690 | Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer | ||
| NCT04955886 | Surufatinib Combined With Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma | ||
| NCT04745741 | Evaluating the Rationality of the International Guideline About Selective Coverage of Level Ib in CTV With NPC | ||
| NCT02845908 | POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC | ||
| NCT04844645 | Using Mini Program for Self-management VS Conventional Pharmaceutical Care for Cancer Pain | ||
| NCT04785768 | IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration | ||
| NCT03708536 | Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma | ||
| NCT03639415 | Change the Dose Frequency of Controlled-Release Oxycodone to Refractory Pain | ||
| NCT03380689 | Phase I Study of Biweekly SIRB Regimen for Metastatic Colorectal Cancer | ||
| NCT03375515 | PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain | ||
| NCT04243954 | Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration | ||
| NCT04734249 | Second-line Surufatinib Combined With Chemotherapy in Advanced CRC | ||
| NCT04613804 | Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy | ||
| NCT04387266 | To Evaluate the Efficacy and Feasibility of Modified Reduce-volume Target IMRT in the Treatment of Patients With Non-metastatic NPC | ||
| NCT04533243 | Opioid Titration With 12.5 ug/h Fentanyl Transdermal Patch vs Orally Morphine for Opioid-naïve Patients With Moderate Cancer Pain | ||
| NCT03648697 | EBV-TCR-T（YT-E001）for Patients With EBV-positive Recurrent or Metastatic NPC | ||
| NCT04354961 | Almonertinib Versus Paclitaxel Plus Carboplatin as First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic Pulmonary Adenosquamous Carcinoma （ARISE） | ||
| NCT04174339 | PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer | ||
| NCT04155671 | POF Versus FOLFOX Plus IP Paclitaxel in AGC | ||
| NCT04149015 | Neoadjuvant POF in the Treatment of Locally Advanced Gastric Cancer | ||
| NCT03788226 | A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer | ||
| NCT04121039 | Study of the Apatinib Combine With POF Versus POF in Gastric Cancer | ||
| NCT04089657 | Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens | ||
| NCT03788174 | Apatinib Combined With POF for Second-line Treatment of Gastric Adenocarcinoma | ||
| NCT03872635 | Effects of Anesthesia on Tumor Immunity and Insulin Resistance During Perioperative Period | ||
| NCT03720873 | EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC | ||
| NCT02697838 | Clinical Trial of Apatinib Reverses Chemotherapy-Resistance of Patients With Advanced Gastric Cancer | ||
| NCT03707639 | Study of the Combination of Apatinib and POF | ||
| NCT03641820 | Cognitive Dysfunction in Patients With Cancer Pain | ||
| NCT03476057 | Next-generation Sequencing in Gastrointestinal Cancer | ||
| NCT03566576 | Phase I Study of the Combination of Anlotinib With Pemetrexed or Docetaxel | ||
| NCT03518489 | Appaconitine Patch for Oral Mucositis Pain Caused by Chemoradiotherapy in Patients With Nasopharyngeal Cancer | ||
| NCT03486509 | Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma | ||
| NCT03486496 | Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation |
